Executive readout · one minute
What the filings say
- 8-K earnings release · filed Nov 9, 2026
- ImmunityBio reported Q3 2026 net product revenue of $48.7 million, up 53% year-over-year; FDA expanded ANKTIVA’s indication for BCG-unresponsive NMIBC, and Israel approval brought global approvals to 35.
- 10-Q report · filed Nov 9, 2026
- ImmunityBio reported ANKTIVA’s October 14, 2026 FDA approval for BCG-unresponsive NMIBC with high-grade papillary-only tumors and Q3 2026 net product revenue of $48.7 million, up 53% year-over-year.
The audio replay and transcript follow the call.